Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
The trial investigates the pharmacokinetic interactions between dapagliflozin, an SGLT2 inhibitor, and two widely used cardiovascular medications, valsartan (an angiotensin receptor blocker) and simvastatin (a statin). Given the increasing prevalence of Type 2 Diabetes Mellitus and cardiovascular diseases, understanding these interactions is critical for optimizing combination therapies. The results may enhance AstraZeneca's positioning in the diabetes and cardiovascular markets, potentially leading to expanded indications for dapagliflozin. Additionally, the collaboration with Bristol-Myers Squibb may strengthen AstraZeneca's portfolio in this therapeutic area. The competitive landscape includes other SGLT2 inhibitors and combination therapies, necessitating a thorough analysis of the trial outcomes to inform strategic decisions.
Indication: Type 2 Diabetes Mellitus
Modality: small molecule
Target: SGLT2 (Sodium-Glucose Cotransporter 2) and Angiotensin II Receptor
Sponsor: AstraZeneca
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SGLT2 (Sodium-Glucose Cotransporter 2) and Angiotensin II Receptor
View original source fields
Condition raw: Type 2 Diabetes Mellitus
Condition normalized: Type 2 Diabetes Mellitus
Modality raw: small molecule
Modality normalized: small molecule
Target raw: SGLT2 (Sodium-Glucose Cotransporter 2) and Angiotensin II Receptor
Target normalized: SGLT2 (Sodium-Glucose Cotransporter 2) and Angiotensin II Receptor